Premium
O2‐15‐06: CSF AMYLOID‐β PEPTIDES IN DEMENTIA WITH LEWY BODIES AND ALZHEIMER'S DISEASE
Author(s) -
Steenoven Inger,
Twaalfhoven Harry,
Flier Wiesje M.,
Teunissen Charlotte E.,
Lemstra Afina W.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.2729
Subject(s) - dementia with lewy bodies , cerebrospinal fluid , dementia , medicine , alzheimer's disease , amyloid (mycology) , logistic regression , pathology , gastroenterology , peptide , disease , biology , biochemistry
Sample 297 82 215 Age 75.15 75.57 75.00 0.89 Mean (s.d.) (6.95) (6.78) (7.02) % Male 61.28 64.63 60 0.46 % ApoE 49.8% 9.75 65.12 < 0.001 Clinical Diagnostic Category (HC:MCI: AD) 83 : 145 : 69 49 : 29 : 4 34 : 116 : 65 <0.001 Education (years) Mean (s.d.) 15.63 (2.95) 15.68 (2.87) 15.61 (2.99) 0.94 CSF Ab1-42 (pg/mL) Mean (s.d.) 167.65 (53.10) 244.60 (25.17) 138.30 (22.94) <0.001 CSF t-tau (pg/mL) Mean (s.d.) 98.80 (54.52) 58.21 (15.51) 114.28 (56.11) <0.001 CSF P-tau (pg/mL) Mean (s.d.) 35.52 (22.10) 20.14 (7.94) 41.43 (22.94) <0.001 Abbreviations: pg/mL1⁄4 picograms per milliliter, s.d.1⁄4 StandardDeviation,%APOE1⁄4 proportion of APOE ε4 carriers, HC1⁄4Healthy Controls,MCI1⁄4Mild Cognitive Impairment, AD 1⁄4 Alzheimer’s disease dementia.